AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19882056
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g oral glucosamine sulphate
Trial: 17492948
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of 17beta‐oestradiol orally combined with 100 mg progesterone
Trial: 17492948
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg of 17beta‐oestradiol transdermally combined with 100 mg progesterone
Trial: 11499745
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (daily walking)
Trial: 9923414
Drug: Tacrolimus (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (target concentration range 10-30 ng/mL during the first 8 weeks, tapering 20% per month during months 3-6)
Trial: 9923414
Drug: Cyclosporine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (target concentration range 150-450 ng/mL during the first 8 weeks, tapering 20% per month during months 3-6)
Trial: 9923414
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and Cyclosporine (both treatments)
Trial: 27147120
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU oral vitamin D weekly for eight weeks
Trial: 27147120
Drug: Placebo weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo weekly for eight weeks
Trial: 19093003
Drug: Rotating cuboid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotating cuboid (non-biological object)
Trial: 8471899
Drug: 3-day norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day norfloxacin treatment
Trial: 8471899
Drug: 7-day norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day norfloxacin treatment
Trial: 31368271
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Sifeng (EX-UE10) combined with Wang's Baochi Pills
Trial: 31368271
Drug: Wang's Baochi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wang's Baochi Pills only (Control)
Trial: 20060162
Drug: 800 mcg
RxNorm normalized name: Biotin 800 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mcg sublingual misoprostol
Trial: 20060161
Drug: 40 IU
RxNorm normalized name: Oxytocin 40 IU/1 ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU intravenous oxytocin
Trial: 8749950
Drug: CISCA chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CISCA chemotherapy with rhG-CSF (lenograstim) at 2 mg/kg/day subcutaneously on days 3 to 16 (until day 14 for the 14-day interval group)
Trial: 8749950
Drug: CISCA chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CISCA chemotherapy with rhG-CSF
Trial: 2611119
Drug: H2 A
RxNorm normalized name: Influenza A virus H2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 A + RF alginate antacid (Riflux Forte)
Trial: 2611119
Drug: H2 A
RxNorm normalized name: Influenza A virus H2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 A + S non‐alginate antacid (Siloxogene)
Trial: 25740264
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (10 g orally once a day for 3 weeks after initial testing)
Trial: 24579364
Drug: Medication (Sanqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Sanqi Tongshu capsules)
Trial: 20466870
Drug: Varenicline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5 mg once daily for days 1-7, 0.5 mg twice daily for days 8-14, 1 mg twice daily for days 15-21)
Trial: 20466870
Drug: Varenicline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5 mg once daily for days 1-14, 0.5 mg twice daily for days 15-21)
Trial: 20466870
Drug: Varenicline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5 mg once daily for days 1-14, 1 mg once daily for days 15-21)
Trial: 15888152
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg kg(‐1)
Trial: 15888152
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg kg(‐1)
Trial: 16618781
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of nonsteroidal anti-inflammatory drugs
Trial: 12456509
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy followed by myeloablative therapy (cyclophosphamide, total body irradiation, and autologous stem cell reinfusion)
Trial: 12456509
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy alone (intermediate-dose melphalan [IDM] without stem cell rescue)
Trial: 12456509
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy followed by myeloablative therapy
Trial: 12456509
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy alone
Trial: 11197214
Drug: Am80 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Am80 therapy
Trial: 11197214
Drug: Am80 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Am80 therapy with subsequent HLA-matched allogeneic bone marrow transplantation (BMT)
Trial: 11197214
Drug: Am80 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Am80 therapy without BMT
Trial: 8899270
Drug: Oral tetrathiomolybdate
RxNorm normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tetrathiomolybdate (TM) followed by oral zinc (Zn) maintenance therapy
Trial: 29710212
Drug: Hyaluronidase (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronidase (1.5, 3.0, or 9.0 U per 0.1 mL)
Trial: 20646412
Drug: Zhibitai (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibitai (480 mg orally twice a day)
Trial: 20646412
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg orally once daily)
Trial: 20646412
Drug: Zhibitai and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibitai and Atorvastatin (both groups)
Trial: 14586167
Drug: Naftidrofuryl (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (400 mg and 600 mg)
Trial: 9280995
Drug: Methadone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (5 mg methadone/5 ml saline) applied to the dura before the end of surgery
Trial: 31809403
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (10, 20, and 40 mg administered over 2 minutes)
Trial: 31809403
Drug: Single-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blind placebo treatment
Trial: 29486598
Drug: New X-ray
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New X-ray imaging platform (AlluraClarity) with reduced dose settings
Trial: 26644222
Drug: Micronutrient-fortified LNS
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified LNS with milk protein base (54 g/day)
Trial: 26644222
Drug: Micronutrient-fortified LNS
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified LNS with soya protein base (54 g/day)
Trial: 26644222
Drug: Micronutrient-fortified corn-soya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified corn-soya blend (71 g/day)
Trial: 24445981
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate and hydroxyzine (40 mg/kg + 2 mg/kg)
Trial: 24445981
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate and promethazine (40 mg/kg + 1 mg/kg)
Trial: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 60 mg/m(2)
Trial: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 75 mg/m(2)
Trial: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 90 mg/m(2)
Trial: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (C) + Doxorubicin (A) + Paclitaxel (175 mg/m(2))
Trial: 10758778
Drug: Artichoke dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke dry extract (1,800 mg per day)
Trial: 8836707
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg a day for 4 days
Trial: 1316058
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg every 8 hours
Trial: 4077578
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and iron supplement (twice weekly)
Trial: 21900849
Drug: Flaxseed bar
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed bar (410 mg of lignans) for 6 weeks
Trial: 20441245
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 600 microg
Trial: 20441245
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 1000 microg
Trial: 20441245
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 1200 microg
Trial: 20441245
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) 1300 microg
Trial: 16240707
Drug: Winex (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Winex (100 mg/5 ml) suspension
Trial: 16240707
Drug: Suprax (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprax (100 mg/5 ml) suspension
Trial: 8576506
Drug: Self-medication program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication program (SMP)
Trial: 1672895
Drug: Generic carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic carbamazepine (100 and 200 mg tablets)
Trial: 7019268
Drug: 0.2% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% aqueous solution of chlorhexidine gluconate
Trial: 31194598
Drug: Six Dried
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six Dried Plums (∼42 g) per day for 2 weeks
Trial: 31194598
Drug: Two Dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Dried Plums (∼14 g) per day for 2 weeks
Trial: 23224687
Drug: Resveratrol-containing grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol-containing grape extract (8 mg resveratrol)
Trial: 18474729
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (220 mg twice daily)
Trial: 17000818
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Trial: 17000818
Drug: Sham intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham intrathecal injection (placebo)
Trial: 12562833
Drug: FAT (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAT (50 g/m2)
Trial: 12562833
Drug: GLUCOSE (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLUCOSE (37.5 g/m2)
Trial: 12562833
Drug: MIXED test
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIXED test (combination of FAT and GLUCOSE)
Trial: 9013365
Drug: Sirolimus (rapamycin)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (rapamycin) at dosage levels from 1 mg/m2/day to 13 mg/m2/day
Trial: 1392995
Drug: Omeprazole for
RxNorm normalized name: omeprazole Granules for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole for four weeks plus bismuth 120 mg, tetracycline 500 mg, and metronidazole 400 mg (all four times a day) for the first week (n = 78)
Trial: 29127137
Drug: Analytic Treatment
RxNorm normalized name: CATALYTIC FORMULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analytic Treatment Interruption (ATI)
Trial: 26847108
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) with additional synthetic disease modifying anti‐rheumatic drugs (sDMARDs)
Trial: 23447917
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Pycnogenol twice daily for 3 months
Trial: 21904014
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow-derived cells (5 cc)
Trial: 21904014
Drug: Whole blood
RxNorm normalized name: Whole blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole blood (5 cc)
Trial: 18498663
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole or 20 mg rabeprazole for 8 days (treatment group)
Trial: 12713711
Drug: Low-dose acetazolamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetazolamide (125 mg BID)
Trial: 11498723
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg NF
Trial: 11498723
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg NF
Trial: 8141572
Drug: Meropenem 1-g
RxNorm normalized name: meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 1-g intravenous intermittent infusions every 8 h
Trial: 29782648
Drug: Topical treatments
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatments for AK
Trial: 25315022
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with Unna's boot
Trial: 21983154
Drug: Quadrivalent live
RxNorm normalized name: influenza vaccine quadrivalent live 2015-2016 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent live attenuated influenza vaccine (Q/LAIV), n=1200
Trial: 21983154
Drug: Trivalent live
RxNorm normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live attenuated influenza vaccine (T/LAIV), n=600
Trial: 17928802
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iron daily for 8 weeks
Trial: 17928802
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg iron daily for 8 weeks
Trial: 17928802
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg iron daily for 8 weeks
Trial: 17928802
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iron group
Trial: 17928802
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg iron group
Trial: 15646910
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of oral midazolam (MDZ) 20 minutes prior to treatment
Trial: 15646910
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg oral midazolam (MDZ) with 3.7 mg/kg of hydroxyzine (MDZH) 30 minutes before treatment
Trial: 15646910
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxyzine (3.7 mg/kg) with MDZ (0.3 mg/kg)
Trial: 28796278
Drug: PNF stretching
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNF stretching (hold-relax-with agonist contraction)
Trial: 20482275
Drug: High-maize 260
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-maize 260 resistant starch (12 g added RS)
Trial: 12357148
Drug: Heparin concentration‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin concentration‐based anticoagulation management (Hepcon HMS)
Trial: 12357148
Drug: Activated clotting
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated clotting time‐based heparin management
Trial: 10348536
Drug: trapidil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trapidil (400 mg/d) + ticlopidine (500 mg) for the first month
Trial: 10348536
Drug: aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (325 mg/d) + ticlopidine (500 mg) for the first month
Trial: 7806173
Drug: Propranolol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.15 mg/Kg intravenously)
Trial: 1719734
Drug: NaCl-infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl-infusions
Trial: 1719734
Drug: Zero or
RxNorm normalized name: Ez2go Zero Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zero or next to zero therapy
Trial: 6176354
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with OK‐432 alone (group B)
Trial: 31310775
Drug: 1 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mcg/kg intravenous ghrelin
Trial: 31310775
Drug: 3 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mcg/kg intravenous ghrelin
Trial: 25049338
Drug: 6-session intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-session intervention based on trauma-focused cognitive behavior therapy
Trial: 18035192
Drug: Amlodipine camsylate
RxNorm normalized name: amlodipine camsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine camsylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Trial: 18035192
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Trial: 12189228
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (900 mg daily, orally for 18 days)
Trial: 2104083
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg t.d.s.)
Trial: 2104083
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg in the evening) without indomethacin
Trial: 2104083
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg in the evening) with concurrent indomethacin
Trial: 370586
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (200 mg per kilogram of body weight per day)
Trial: 27817766
Drug: Somatostatin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (0.25 mg initial dose and 0.25 mg/h for maintenance)
Trial: 27817766
Drug: Somatostatin (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (3.5 μg/(kg·h) continuous intravenous pumping)
Trial: 17592905
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic agents (adjunctive treatment)
Trial: 17592905
Drug: Placebo (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (adjunctive treatment)
Trial: 12818732
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL 25 mg once daily
Trial: 8867274
Drug: Wobenzym (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wobenzym (4 x 7 capsules/day)